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Plants are important resources in healthcare and for producing pharmaceutical drugs.
Pharmacological and phytochemical characterization contributes to both the safe use
of herbal medicines and the identification of leads for drug development. However,
there is no recent assessment of the proportion of plants used in ethnomedicine that
are characterized in this way. Further, although it is increasingly apparent that plants
used in ethnomedicine belong to preferred phylogenetic lineages, it is not known how
this relates to the focusing of research effort. Here we identify species and lineages
rich in ethnomedicinal use and develop methods to describe how well they are known
pharmacologically and/or phytochemically. We find 50% of plant species of the family
Leguminosae used in ethnomedicine in Brazil, a geographical area where plants are an
important part of healthcare, have been the focus of either phytochemical screening or
testing for biological activity. Plant species which have more use reports are studied
significantly more often (p < 0.05). Considering the taxonomic distribution of use, 70%
of genera that include species with ethnomedicinal use have been studied, compared
to 19% of genera with no reported use. Using a novel phylogenetic framework, we
show that lineages with significantly greater numbers of ethnomedicinal species are
phylogenetically over-dispersed within the family, highlighting the diversity of species
used. “Hotnode clades” contain 16% of species but 46% of ethnomedicinally-used
species. The ethnomedicinal species in hotnode clades have more use reports per
species (p < 0.05), suggesting they are more frequently used. They are also more
likely to be characterized pharmacologically and/or phytochemically. Research focus
has followed traditional use by these measures, at least for these Brazilian plants, yet
ethnomedicinal species yielding candidate drugs, raising public health concerns and
more intensively studied lie outside of the hotnode clades.
Keywords: ethnopharmacology, Brazil, bioprospecting, leguminosae, traditional use, ethnobotany
INTRODUCTION
Plants are the primary health care resource in many communities around the world (Bannerman
et al., 1983). They also serve as resources for the development of biomedicines, and traditionally-
used species have contributed significantly to the development of biomedical drugs (Newman
et al., 2000; Fabricant and Farnsworth, 2001; Cragg and Newman, 2013). It has been argued
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that ethnomedicinal use can be used to focus bioprospecting,
addressing the decline in leads (Nwaka and Hudson, 2006)
by provisioning new chemical entities or combinations of
metabolites for testing (Gurib-Fakim, 2006; Sucher, 2013; Skirycz
et al., 2016). Whether this is true or not, investigation of plants
used in ethnomedicine is needed because public health may be
compromised by ongoing use of some plants raises concerns
(Jäger, 2015). Given these twin drivers of research, it might be
expected that traditionally used plants are known rather well.
However, there is a lack of knowledge about how well plants
in general have been characterized; there are no explicit studies
to investigate whether plants of ethnomedicinal importance
are well known, and no recent data are available. The most
cited source regarding the deficit of knowledge of plants comes
from Verpoorte (1998), cited in Verpoorte (2000) and Fabricant
and Farnsworth (2001). Verpoorte (1998) estimated that 6%
of all plant species were screened for biological activity, and
15% evaluated phytochemically, but did not consider whether
species were used in ethnomedicine. His estimates were made by
compiling a count of the number of species in the NAPRALERT
database against an estimate of total number of species.
Humans make direct use of only a proportion of the plant
species around them, and it has long been known that plants
with medicinal use are usually found more frequently in some
families than in others (Moerman, 1991; Moerman et al.,
1999). Phylogenetic methods are emerging as useful tools to
describe these patterns (Saslis-Lagoudakis et al., 2011, 2012; Ernst
et al., 2016).The well-known association of phytochemistry with
taxonomy (Gibbs, 1974) is also increasingly better understood
in terms of phylogeny (Wink, 2013). If lineages rich in species
with ethnomedicinal use are those that have metabolites of
interest, phylogenetic methods predict bioprospecting potential
(Saslis-Lagoudakis et al., 2011; Ernst et al., 2016). Direct tests
of phylogenetic structuring of phytochemistry for groups of
ethnomedicinal and bioprospecting interest show that some (e.g.,
Rønsted et al., 2008) but not all (e.g., Grimbs et al., 2017) reveal
phylogenetic signal. Nevertheless, it seems probable that close
relatives of species of interest might yield larger quantities, or
interesting variants, of valuable compounds.
The Leguminosae is one of the largest plant families (Lewis
et al., 2005). With many documented uses, the family is over-
utilized for medicine in some regions (Korea and Ecuador)
but under-utilized in others (North America) (Moerman et al.,
1999). Close-related species share similar secondary metabolites
that could be of interest (Wink, 2003) and phylogenetic
structure in the distribution of secondary metabolites has been
well documented for the family (Wink, 2013). In Brazil, the
Leguminosae comprises c. 2,800 species in more than 200
genera (Flora of Brazil 2020 in Construction, 2016). The species
diversity, widespread distribution, and many reported uses
(Souza and Hawkins, 2017), and the availability of phylogenetic
information (Legume Phylogeny Working Group [LPWG], 2013)
have prompted us to select the family as a case study. We focus
on Brazil since its vast biodiversity is a potential source of new
medicines as well as a source of primary health care: it is estimated
that 66% of the population has no access to commercial drugs
(Mazzari and Prieto, 2014).
The objective of this study was to provide a contemporary
estimate of the extent to which the plants used in
ethnomedicine have been investigated phytochemically and/or
pharmacologically and relate this to the ethnomedicinal
importance of the plant species and their lineages.
Ethnomedicinal importance was estimated from the
frequency of use reports in our existing compilation of
ethnomedicinal Leguminosae in Brazil (Souza and Hawkins,
2017; www.ewedb.com). To identify ethnomedicinally important
lineages, we made a phylogenetic study of the medicinal uses
of our target group, the Leguminosae. Until now, phylogenetic
investigations of ethnomedicinal plants have considered global
floras (Halse-Gramkow et al., 2016), whole floras (e.g., Saslis-
Lagoudakis et al., 2012) or genera throughout their range (e.g.,
Saslis-Lagoudakis et al., 2011; Ernst et al., 2016). As well as being
the first study focused at family level, this study is also the first
to study the frequency of reported use per species, in order to
elucidate the phylogenetic relationships of ethnomedicinally
important plants. Ultimately, we present a set of measures that
show how research effort on plants with ethnomedicinal use, and
their relatives, is focused.
MATERIALS AND METHODS
Ethnomedicinal Use of Legumes in Brazil
Published ethnomedicinal use data compiled for the
Leguminosae of Brazil (Souza and Hawkins, 2017;
www.ewedb.com) were used for this study. Publications
citing ethnomedicinal uses of Leguminosae species in Brazil
were identified using online citation indices. We also used direct
searches of unindexed journals, including the following journals
not indexed by PubMed: Acta Botanica Brasilica, Flovet, Revista
Brasileira de Biociencias, Revista Brasileira de Farmacognosia,
Revista Brasileira de Plantas Medicinais, and Rodriguesia.
Herbarium data was extracted from the online list of herbarium
and biological collections from Brazil, Species Link1. The file
was exported to excel format and a search using the keywords
“medicinal” and “uses” (in Portuguese) was conducted to select
only the specimens with ethnomedicinal information. Generic
and species names followed the Flora of Brazil (Brazilian Flora,
2020), and were corrected (standardized) using the Plantminer R
script (Carvalho et al., 2010).
Pharmacology of Species Used in Brazil
Pharmacological data associated with the Brazilian
ethnomedicinal species, and for all genera, whether used or
not, were sought online using online citation indices including
“Web of Science” (WoS). Search terms included the species name
and commonly used synonyms, together with “pharmacolog∗”.
The number of results from WoS for each species was recorded,
together with publications related to pharmacological studies. As
for ethnomedicinal use, names were standardized to follow the
Flora of Brazil (Brazilian Flora, 2020).
1http://splink.cria.org.br/
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Analysis
From our surveys, we compiled data describing the presence or
absence of use reports (citation of ethnomedicinal use in the
literature) at species and generic level, and the number of use
reports at species level. We scored whether each species was
the subject of pharmacological research, and record research
effort for each species as the number of published studies
that investigate each species. We performed Spearman’s Rank
Correlation test at species level to determine whether species
with more use reports were the focus of more pharmacological
research effort.
To understand the distribution of ethnomedicinal species in
the family, a phylogenetic tree for the Leguminosae in Brazil was
reconstructed at genus level, with one species per genus being
sampled. Sequences from the DNA marker MatK were compiled
from the Tree of Legumes (Legume Phylogeny Working Group
[LPWG], 2013) when present, and from publicly available
sequences on Genbank. All accession numbers are detailed in
Supplementary Table S1. In total, 203 genera were sampled
(92.7% of the total flora). Sequences were aligned using MUSCLE
alignment available in Geneious 8.0 and adjustments were made
manually. Sequence data was analyzed under the maximum-
likelihood (ML) criterion, under the GRTGAMMA model as
implemented in RAxML 7.2.8 (Stamatakis, 2014). Unsampled
genera and species were added manually as polytomies using
the R package PHYTOOLS and the function add.species.to.genus
to generate a species tree (Revell, 2012). To make the tree
ultrametric, we used the function chronos from the package APE
(Paradis et al., 2004). The phylogenetic hypothesis obtained was
compared to the Tree of Legumes (Legume Phylogeny Working
Group [LPWG], 2013).
Having confirmed our phylogeny was congruent with the
existing hypothesis for the Leguminosae, the phylogenetic
structure of ethnomedicinal uses was investigated using tools
widely used in community phylogenetics (Pearse et al., 2014).
We calculated the Net Relatedness Index (NRI) and Nearest
Taxon Index (NTI) (Webb, 2000; Webb et al., 2002), with the
functions ses.mpd and ses.mntd from the PICANTE package
(Kembel et al., 2010). The chosen null model was “taxa.labels”,
which shuﬄes the distance matrix labels across all taxa included
in distance matrix with 999 runs. The NRI and NTI values
were obtained by multiplying the MPD (Mean phylogenetic
distance) and MNTD (Mean Nearest Taxon Distance) values
by −1. The NRI value represents the average distance between
a species and all other species with the same characteristic (in
our case ethnomedicinal use). Higher values of NRI (negative
for MPD) indicates a phylogenetic clustering of a sample, while
negative values (positive for MPD) show an overdispersion of
the studied taxa. Similarly, NTI (and MNTD) values can indicate
clustering or dispersion (Figure 1). According to Webb (2000),
NRI values describe a deep relationship in the phylogeny, which
here might be evidence for clustering or overdispersal at tribal or
sub familial levels. On the other hand, NTI describes relatedness
in terminal clades, in our case clustering or overdispersion of
congeneric ethnomedicinal plants (see also Mazel et al., 2016).
Phylogenetic structure was investigated for the ethnomedicinal
species compared to the whole Leguminosae flora in Brazil.
“Hotnode clades” (as described by Saslis-Lagoudakis et al., 2012)
were sought using the NODESIG function in also in R (R Core
Team, 2015) adapted by Abellán et al. (2016).
The phylogenetic framework was used to address the following
questions:
1. Are there more species that have been the focus of
pharmacological study within the lineages that are hotnode
clades for ethnomedicinal use?
2. Is intensity of use of species for ethnomedicine greater in the
lineages that are in hotnode clades for ethnomedicinal use
3. Is the intensity of research effort greater within hotnode
clades?
4. Do hotnode clades yield more drugs?
Intensity of ethnomedicinal use was estimated based on the
number of citations/use reports in the database. Intensity of
research effort was measured by counting the number of reported
studies (publications) for each species. The intensity of research
effort was compared for the species ethnomedicinally-used for
medicine inside and outside of the hotnode clades. A Wilcoxon
test was used to determine whether there are significantly more
pharmacological studies outside of hotnode clades than would be
expected if pharmacological effort was homogeneous.
To assess whether traditional use coincides with development
of commercial drugs we extracted the list of genera yielding FDA-
approved and clinical-trial drugs (drug genera) from the recent
large-scale study of Zhu et al. (2011) and recorded the number of
genera found in Brazil. We also recorded whether these genera
were present in hotnode clades.
All underlying research data is available from the
corresponding author.
RESULTS
Data Description
There were 286 species (10% of the total legume flora) in
104 genera (48% of the total legume genera) reported to have
ethnomedicinal use (Figure 2). The pharmacological review
identified 98 genera that had been screened (43% of genera).
There were 143 ethnomedicinally-used species (50% of the
species used) that had been the focus of research described
in 3047 publications abstracted by the Web of Science. The
ethnomedicinally-used species that had been screened are found
in 77 genera, thus 72% of genera with ethnomedicinal use
had been the focus of pharmacological study. A much lower
percentage of the 118 genera without any ethnomedicinal use
had been studied (22 genera, 19%). The Spearman’s Rank
Correlation showed significant positive correlation between use
and pharmacological study at the species level (p< 0.05; ρ = 0.36).
Phylogenetic Analysis
The phylogeny we reconstructed (Supplementary File S1)
was congruent with current hypotheses of relationship for
the Leguminosae. The investigation of the phylogenetic
structure of ethnomedicinal species for medicine shows
an over-dispersed structure for overall ethnomedicinal use
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FIGURE 1 | Schematic representation of scenarios of relatedness. Clustering and overdispersion are inferred from MPD and MNTD values (and their related NRI and
NTI indices respectively). MPD describes relationships that occurred on deep nodes of the phylogeny, while MNDT reflects relationships at shallower nodes.
Combined values can be used to infer different scenarios. Blue, phylogenetic clustering, MPD and MNTD positive; black, overdispersion of clustering, MPD negative
and MNTD positive; pink, clustering of overdispersion, MPD positive and MNTD negative; red, phylogenetic overdispersion, MPD negative and MNTD negative. The
phylogenetic tree was generated with the function “rtree” from the package ape using R.
(NRI and NTI < 0, p < 0.05) (Figure 3). The same pattern
of overdispersal was found for therapeutic applications
considered separately (Supplementary Table S2). The
Nodesig analysis showed 126 ethnomedicinal species (44%
of species with at least one use report) were inside hotnode
clades, but only 16% of the total flora (Figure 2 and
Table 1).
1. There are more species that have been the focus of
pharmacological study within the lineages that are hotnode
clades for ethnomedicinal use. Of the 126 hotnode clade
species with ethnomedicinal use, 74 (16% of all hotnode clade
species) were the focus of at least one pharmacological study.
A lower number, 73 species (3% of all non-hotnode clade
species) of the 150 ethnomedicinal species outside hotnode
clades had been screened (Table 1) revealing a preference for
screening ethnomedicinal species that are in hotnode clades.
2. The intensity of ethnomedicinal use of species for medicine
is greater in the lineages that are hotnode clades for
ethnomedicinal use. Species with ethnomedicinal use present
in the hotnode clades were cited almost twice as often as the
ones outside the hotnode clades (p< 0.05; Table 1).
3. The intensity of research effort is not significantly greater for
ethnomedicinal species inside hotnode clades. Although there
were numerically more species from hotnodes screened, no
significant difference was found for the intensity of screening
between ethnomedicinal species inside and ethnomedicinal
species outside of hotnode clades. In fact, ethnomedicinal
species outside hotnode clades are more studied. Figure 4
shows on a phylogeny how intensity of use and intensity of
study are distributed.
4. Hotnode clades yield fewer drugs approved by FDA for use
or clinical trials. We identified 16 genera found in Brazil that
include species (not necessarily from Brazil) that have yielded
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FIGURE 2 | Comparison of ethnomedicinal selection and pharmacological research effort. The left “column” (dark gray) shows the decreasing numbers of potential
leads, if focus is on taxa (middle row) or lineages (bottom row) with ethnomedicinal use. This column shows that a focus on ethnomedicinal hotnode clades reduces
the size of the species pool from 2837 species in total to 126 species that have ethnomedicinal use and are inside a hotnode clade. The arrows show the
proportions of total flora represented in the samples, for example, the 126 species with ethnomedicinal use in the bottom row represent 4% of all species. This is 4%
of all species. The right “column” (light gray) shows the proportion of these taxa that have been screened according to our survey. If focus is on the whole flora, there
are 98 genera that have been investigated pharmacologically (43% of all genera). Considering the ethnomedicinally important lineages (bottom row), there are 34
genera with ethnomedicinal use and have been characterized pharmacologically that belong to hotnode clades (92% of the genera with ethnomedicinal use and in
hot modes). The circled numbers in blue show the number of species that have yielded drugs approved for use or clinical trial by the FDA. As focus on
ethnomedicinally important groups increases, there is a concomitant increase in research effort, but fewer drugs approved for use or clinical trial by the FDA.
drugs approved for use or clinical trial by the FDA. We found
that 11/14 of these genera have species with ethnomedicinal
use in Brazil, and that only 2/11 of these genera belong to
hotnode clades. Table 2 shows the therapeutic applications
recorded for all Brazilian species belonging to these genera,
and indicates whether each genus belong to a hotnode.
DISCUSSION
This study reveals that half of the species of Leguminosae used
in ethnomedicine in Brazil have been the focus of at least one
phytochemical or pharmacological study. Despite the importance
of ethnomedicinal plants in bioprospecting and local health care,
the frequently cited global estimates of 9% of plants screened
do not consider whether plants are used in ethnomedicine or
not (Fabricant and Farnsworth, 2001). Although ethnomedicinal
use is not taken into account, and this figure is now more than
15 years old, it probably remains our best estimate of how well
known are the properties of ethnomedicinally important plants.
Our study is an original insight into this question, and shows
that at least for some ethnomedicinally important plant lineages
in some parts of the world, there is now considerable scientific
knowledge of the properties of plants. The consideration of
the relationship between pharmacological study and intensity of
ethnomedicinal use we present here is a timely first step towards
a data-driven evaluation of how ethnomedicine might inform
bioprospecting, or direct research into the health risks associated
with local plant-based healthcare.
A wider audit is needed to determine whether our estimate
of 50% of plants screened applies beyond the geographical and
taxonomic limits of our study. Investment in natural products
research informed by traditional knowledge has fluctuated
(Koehn and Carter, 2005), and while there may be many
factors at play, Brazil has invested in realizing the value of
local and indigenous knowledge of indigenous plant resources
through pharmacological research (Dutra et al., 2016). This
might suggest that Brazilian plants could be rather well known
compared to plants in other biodiversity hotspots. However,
our findings should be considered in the light of Brazilian
government policy to integrate herbal medicines into their
healthcare system. Because of the huge number of plant species
used medicinally in Brazil, the Health Ministry policy focused
efforts on elucidating the efficacy and safety of 71 promoted
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FIGURE 3 | Distribution of medicinal uses and pharmacological studies in the
Leguminosae phylogeny and “Hotnode clades” for ethnomedicinal use. Block
colors at the tips: purple, ethnomedicinal use for that genus; black,
pharmacological studies for that genus. Branch colors: red branches, genera
present in hotnode clades for species with ethnomedicinal use. Clade colors:
yellow, grey, green, light blue and brown indicate membership of subfamilies.
Figure prepared using iTOL online (Letunic and Bork, 2016).
TABLE 1 | Characterization of “hotnode clades” in terms of absolute numbers and
proportions of species and studies.
Hotnode clades Outside
Number of genera with ethnomedicinal use 37 (74%) 65 (42%)
Number of genera with pharmacological study 34 (68%) 60 (39%)
Number of species with ethnomedicinal use 126 (28%) 150 (6%)
Number of species with pharmacological study 74 (16%) 73 (3%)
Intensity of ethnomedicinal use (Number of
citations)
1192 549
Intensity of pharmacological study (Number of
studies)
1028 1665
Average number of studies per ethnomedicinal
species
13 22
Proportions are reported according to the total number of species in hotnode
clades (446 species) and outside of hotnode clades (2331), and according to the
total number of genera in hotnode clades (50) and outside hotnode clades (152).
Genera with ethnomedicinal use are genera which include at least one species with
one use report. Genera with pharmacological study include at least one species
included in a publication describing pharmacological study. Citations refers to the
number of use reports a species has in the database for ethnomedicinal use.
Studies refers to the number of publications describing pharmacological study.
ethnomedicinal plant species (Ministério da Saude, 2009; SUS,
2009; Mazzari and Prieto, 2014). It might be expected that there
have been fewer resources directed towards characterization of
non-list species, though seven of the listed species belong to
family Leguminosae. That many species are found outside of
Brazil and we did not limit our survey of research effort to
Brazilian research groups might increase likelihood of screening
of plants. The family Leguminosae is a rather well-known plant
family taxonomically, so it will be interesting to see whether it is
better-known than other families. Our study might serve as a start
point from which an evolutionarily-informed audit of scientific
knowledge of ethnomedicinal plants could be developed.
The approach taken here goes far beyond counting the
number of species used in ethnomedicine and recording whether
these plants are the focus of pharmacological studies. We
use a phylogenetic framework to identify evolutionary lineages
that are particularly important in ethnomedicine, and record
whether species in those lineages are more often screened than
other ethnomedicinal plants. A first step was the phylogenetic
characterization of ethnomedicinal species of Leguminosae in
Brazil plants, and we revealed novel patterns with significant
implications for bioprospecting. Previous phylogenetic studies
reported clustering of species with ethnomedicinal use, both for
whole floras (Saslis-Lagoudakis et al., 2012), and when species
level phylogenies are used to interrogate the patterns of plant
use in genera (Saslis-Lagoudakis et al., 2011; Ernst et al., 2016).
Our study is the first focused at the level of a plant family, and
also the first to recover a signal of phylogenetic overdispersal
(Table 1). Phylogenetically-informed bioprospecting until now
has been concerned with clustering, whether recovered using
D-statistics (Rønsted et al., 2008), Pagel’s lambda (Cámara-
Leret et al., 2017), or community phylogenetic methods (Saslis-
Lagoudakis et al., 2011, 2012, 2014; Yessoufou et al., 2015;
Ernst et al., 2016; Halse-Gramkow et al., 2016). Overdispersal
challenges the established use of phylogeny as a predictive
tool to inform ethnopharmacological screening, but here we
show that hotnode clades can still be identified and lineages of
interest highlighted (Figure 2). Bioactivity of plant species is
related to the presence of secondary metabolites that mediate
interactions of plant species with pathogens and herbivores,
other plants, and pollinators (Bourgaud et al., 2001; Edris,
2007; Heil, 2008; Huang et al., 2012). While some metabolites
in the legumes, such as flavonoids, triterpenes, and pinitol,
are of broad occurrence and can be found in diverse groups,
others are limited in their phylogenetic distribution (Wink,
2013). The pattern of overdispersal we find here might result
from the adoption of multiple lineages with different secondary
metabolites for ethnomedicine. The interplay of chemical and
phylogenetic diversity underscores that the hierarchical level of
the study is important in devising and interpreting any study.
Saslis-Lagoudakis et al. (2012) indicated in a study across all
Angiosperms that plants of the Leguminosae were included in
cross-cultural hotnode clades. However, in this study at the
family level, overdispersal reveals phylogenetically non-random
use, comprising overdispersed lineages that we hypothesis here
are selected for their diverse chemistries. Many more studies are
needed to determine how general these emerging patterns are,
and whether they apply to less species-rich families. In the context
of what might be overdispersed clusters (Figure 1) a fresh view of
priorities for pharmacological research effort can be made.
Our data show how pharmacological studies are distributed
relative to hotnode clades. Although hotnode clades comprise
only 14% of total species they include almost half of the
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FIGURE 4 | Comparison between hotnode clades (A) and other nodes (B) in relation to number of citations (blue) and number of pharmacological studies (orange).
Hotnode clades are calculated based on the distribution of recorded use of species. Species in hotnode clades have significantly more use reports (p < 0.05). Figure
prepared using iTOL online (Letunic and Bork, 2016).
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ethnomedicinal species. As well as being evolutionary hotspots
for ethnomedicinal species, overall the hotnode clades encompass
significantly more use reports. These same hotnode clades also
include more than half of the ethnomedicinally used species
that have been the focus of pharmacological investigation. Our
study corroborates the view that ethnomedicinal use guides
pharmacological research (Gurib-Fakim, 2006), showing that
close relatives of ethnomedicinal plants are also the focus of
study. Using a phylogenetic framework we highlight here how
just a small part of the phylogeny concentrates both traditional
knowledge and pharmacological research, whilst overall the
diversity of ethnomedicinal species outside of hotnode clades are
relatively poorly known.
Emphasis on few lineages would benefit bioprospecting if
valuable leads are more likely to be encountered in hotnode
clades. A total of 35 species belonging to 25 genera in
family Leguminosae, 14 of which are found in Brazil, yield
44 of the products approved for clinical trial by the FDA
(Zhu et al., 2011). Only two genera of the 15, Senna and
Vachellia, fall into a Brazilian hotnode clade. This is in
complete contrast to the findings of Saslis-Lagoudakis et al.
(2012), who found a significant association between approval
and membership of hotnode clades. The discrepancy might
be attributed to the different hierarchical level of study, or
to the choice of Leguminosae as a study group. Whilst the
whole Leguminosae falls into a hotnode clade in the study of
three floras (Saslis-Lagoudakis et al., 2012), focusing the study
on the family means that lineages within the Leguminosae
are discriminated. We suggest here that our hotnode clades
include plants of mild action, whilst clinical investigation has
prioritized species of relatively high toxicity. It is known,
for example, that species of family Leguminosae used as
contraceptives or abortifacients show high toxicity and yield
anticancer therapeutics (Leonti et al., 2017). To illustrate the
relationship between mild action and frequent use, we can
contrast uses of species of two genera, selected here because
they are of similar size and exemplify genera inside and
outside of hotnode clades, Crotalaria and Copaifera. Crotalaria
is represented by 42 species in Brazil, five of which are used
based on 15 use reports. Use of these species in Brazilian
ethnomedicine is for very specific applications, including as
abortifacients or vermifuges. Crotalaria species contain the
pyrrolizidine alkaloid (PA) monocrotaline, which has been
investigated as an anti-tumor agent (Kusuma et al., 2014).
In contrast, the 26 species of Copaifera in Brazil, known
to be of mild effect, have 70 use reports for six species.
Crotalaria, unlike Copaifera, does not belong to a hotnode
clade but is nested in a clade with Sophora (1 species, one
use report), Ulex (1 species, not used), Sellocharis (1 species,
not used) and Lupinus (31 species, none used), all plants with
PAs (Wink, 2013). Copaifera and its close relatives in the
hotnode clade (Eperua, Hymenea; Figure 2) contain diterpene
resins with antimicrobial activity. These data exemplify the
infrequent traditional use of toxic species and their relatives,
compared to the species of mild effect in common use.
If novel drug leads from the Leguminosae are developed
for their cytotoxicity, then bioprospecting effort should be
focused on species outside of hotnode clades. In the case
of Crotalaria, ultimately monocrotaline was shown to be a
hepatocarcinogen which causes pulmonary hypertension and
veno-occlusive disease (e.g., Knutsen et al., 2017). Although many
plants of high toxicity do not ultimately become commercialized
therapeutics, the potential of more toxic products might explain
the predominance of plants outside of hotnode clades in the
FDA lists (Table 2). We find that although fewer ethnomedicinal
species outside of hotnode clades are studied, but when they
are there are more studies published. This finding might further
support the view that these plants are toxic or have potential as
leads.
Whether or not novel leads remain to be discovered, there
are compelling reasons to characterize plants that represent
different lineages in ethnomedicine. Lack of knowledge may be
problematic because health risks associated with ethnomedicinal
plant use may be unreported (Jäger, 2015). Studies on safety,
and especially well-conducted clinical trials, are rare in Brazil
(Dutra et al., 2016). Mazzari and Prieto (2014) highlighted
TABLE 2 | The 16 genera found in Brazil that include species (not necessarily from Brazil) that have yielded drugs approved for use or clinical trial by the FDA and their
ethnomedicinal use, if any, in Brazil.
Genera yielding drugs approved
by FDA for use of clinical trial
Drug (therapeutic class or targeted disease)
(Zhu et al., 2011)
Presence in hotnode? Therapeutic application of species in that
genus in Brazil (frequency of citation)
Acacia Amphetamine (neurological disease) No DFS (1)
Atenolol (cardiovascular disease)
Betaxololo HCI (cardiovascular disease)
Dextroamphetamin e sulfate (ADHD; narcolepsy)
Isoprenaline (Cardiovascular disease)
Methamphetamine (neurological disease)
Metoprolol tartrate (Cardiovascular disease)
Polyphenon 100 (Haemostatic)
Propranolol (Cardiovascular disease)
Tranylcypromine sulfate (Major depressive)
Vyvanse (Neurological disease)
(Continued)
Frontiers in Plant Science | www.frontiersin.org 8 June 2018 | Volume 9 | Article 834
fpls-09-00834 June 19, 2018 Time: 16:11 # 9
Souza et al. Ethnomedicine-Phylogeny and Research Effort
TABLE 2 | Continued
Genera yielding drugs approved
by FDA for use of clinical trial
Drug (therapeutic class or targeted disease)
(Zhu et al., 2011)
Presence in hotnode? Therapeutic application of species in that
genus in Brazil (frequency of citation)
Senegalia Atenolol (cardiovascular disease) No DFS (1), DMC (3), DRS (5), IPD(2)
Betaxololo HCI (cardiovascular disease)
Amphetamine (neurological disease)
Dextroamphetamin e sulfate (ADHD; narcolepsy)
Isoprenaline (Cardiovascular disease)
Lisdexamfetamine dimesylate (ADHD)
Methamphetamine (neurological disease)
Metoprolol tartrate (Cardiovascular disease)
Propranolol (Cardiovascular disease)
Tranylcypromine sulfate (Major depressive)
Vyvanse (Neurological disease)
Cassia (Senna) Danthron (laxative)
Sennoside A (Cardiovascular disease)
Sennoside B (Cardiovascular disease)
Yes Other (tanning) (Cassia). Senna— DBI (5),
DCS (12), DDS (35), DFS (11), DGS (9), DMC
(7), DNS (6), DRS (27), DSS (10), ENM (8), IPD
(9), NEO (3), PCP (3)
Melilotus Hidrosmin (Cardiovascular disease) No Medicinal
Warfarin (Cardiovascular disease)
Mucuna L-Dopa (Neurological disease) No Medicinal
Levodopa (dietary supplement)
Melevodopa (Neurological disease)
Crotalaria Monocrotaline (oncological disease) No DFS (1), IPD (1)
Sophora Pachycarpine (Oxytocic) No Medicinal
Sofalcone (Antiulcer)
Daidzein (oncological disease)
Phenoxodiol (Oncological disease)
Trifolium Pinitol (Expectorant) No not used as medicinal in Brazil
Daidzein (oncological disease)
Phenoxodiol (Oncological disease)
Lonchocarpus Rotenone (Piscicide) No not used as medicinal in Brazil
Phaseolus Daidzein (oncological disease) No ENM (1), IPD (1)
Phenoxodiol (Oncological disease)
Pueraria Daidzein (oncological disease) No not used as medicinal in Brazil
Phenoxodiol (Oncological disease)
Vigna Daidzein (oncological disease) No DSS (1)
Phenoxodiol (Oncological disease)
Indigofera Indirubin (oncological disease) No DDS (2), DGS (2), DNS (1), PCP (1)
Vachellia Pinitol (Expectorant) Yes DDS (2), DEA (1), DMC (2), DNS (1), DRS (2)
For each genus we indicate the drug following Zhu et al., 2011, whether the genus is in a hotnode clade, the therapeutic applications of Brazilian species and the frequency
of citation. Therapeutic applications are as follows: DBI, diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism; DCS,
diseases of the circulatory system, DDS, diseases of the digestive system; DFS, diseases of the femalegenito system; DGS, diseases of the genitourinary system; DMC,
diseases of the musculoskeletal system and connective tissue; DNS, diseases of the nervous system; DRS, diseases of the respiratory system; DSS, diseases of the skin
and subcutaneous tissue; ENM, endocrine, nutritional, and metabolic diseases; IPD, certain infectious and parasitic diseases; NEO, neoplasms; OTHER, not classified
diseases such as fever, pain, and inflammation.
little attention, in the Brazilian context, to the safety of herbal
medicines. We show studies characterizing plants are most
often of commonly used species from hotnode clades. For
example, Brazilian species belonging to the Leguminosae genera
Stryphnodendron (Costa et al., 2013), Erythrina (Dias et al.,
2013), and Pterodon (Dutra et al., 2016), including plants used
extensively in local medicine, have been the focus of recent
pharmacological and toxicological survey without substantiating
concerns. Stryphnodendron adstringens and Erythrina mulungu
are listed by the Brazilian Health Ministry as priority species,
and are found in our hotnode clades; Caesalpinia ferrea and
Bauhinia variegata are also found in hotnode clades and are
listed by the Brazilian Health Ministry. Plants outside of the
hotnode clades are particularly poorly known, and it is notable
that the only plant of family Leguminosae in the Brazilian Health
Ministry list that is not either a common and global agricultural
food or fodder plant or in a hot node is Dalbergia subcymosa, a
plant with few reported uses in women’s medicine and relatively
poorly known from a pharmacological or phytochemical
perspective. Phylogenetic methods could be used in
Frontiers in Plant Science | www.frontiersin.org 9 June 2018 | Volume 9 | Article 834
fpls-09-00834 June 19, 2018 Time: 16:11 # 10
Souza et al. Ethnomedicine-Phylogeny and Research Effort
tandem with ethnobotanical databases to predict the health
risks associated with uncharacterized plant species. Here we
show that lineages rich in ethnomedicinal use have more
ethnomedicinal species that are the focus of pharmacological
studies, showing effort is directed towards characterizing closely-
related, most-used species. Just as for bioprospecting purposes,
it could be argued that phylogenetically-isolated species should
be consciously included in future research. Plants outside
of hotnode clades may raise more concerns for the safety
of the users of traditional medicine, though they are less
used.
Our study considered the presence or absence of
ethnomedicinal use, and the presence or absence of
phytochemical or pharmacological studies. We also considered
intensity of ethnomedicinal use, where the number of use
reports served as a proxy for intensity of use. Research effort
was recorded by recording the number of published studies
we found in our online searches. We are confident in our
estimation of presence of ethnomedicinal use, since we make
a thorough survey of literature and herbarium records (Souza
and Hawkins, 2017). We consider number of use reports to be a
reasonable estimate of ethnomedicinal intensity of use, though
in the case of flowers, fruits, and seeds, their infrequent use
may be their seasonal availability may reduce the number of
reports (Benko-Iseppon and Crovella, 2010). Counting papers
to estimate research effort may be more flawed. Firstly, it is
difficult to make a complete search when publications might
use a range of very broad or specific key words. Further, the
actual studies may be more revealing than the fact that they
exist. Although many pharmacological studies were found for
the ethnomedicinal species, the quality and significance of the
studies were not easily assessed. Many low impact studies use
meaningless bioassays, and report differences between in vitro
and in vivo experiments that are a consequence of data quality
(Gertsch, 2009). Finally, we explore only ethnomedicinal use and
phylogeny as potential factors contributing to the selection of
a species for phytochemical or pharmacological studies. Other
factors may be important, for example the availability of plentiful
plant material (Atanasov et al., 2015); we note the species that are
the most intensively screened often have food or fodder use, for
example Canavalia species are used as food for cattle. Existing
protocols and emerging interest may create a snowball effect, so
that many studies are made of species of already proven interest,
or of their close relatives.
Brazil is a megadiverse country with a rich history of plant
use for medicine, but this knowledge and natural resource is
yet to be transformed into products. Although ultimately the
regulatory and research infrastructure together determine the
success or failure of the drug development pipeline, here we
consider aspects at the interface between traditional knowledge
and biodiversity. This study shines a light on the phylogenetic
distribution of ethnomedicinal plants in family Leguminosae
from Brazil. In highlighting an overdispersed structure for the
first time it draws attention to the complex nature of plant
selection for ethnomedicinal use. It also highlights a connection
between lineages of importance for ethnomedicine and those
that have become the focus of ethnopharmacological research,
raising questions about the drivers of selection of species for
screening in pharmacological studies. Much has been written
about means devising rational, data-driven selection of plants
for screening, for example by inferring useful phytochemical
composition from ethnobotanical, chemosystematic or ecological
information (Coley et al., 2003; Tan et al., 2006; Douwes et al.,
2008; de Albuquerque, 2010; Saslis-Lagoudakis et al., 2011;
Albuquerque et al., 2012), or from phylogeny (Rønsted et al.,
2008; Saslis-Lagoudakis et al., 2012; Grace et al., 2015; Yessoufou
et al., 2015; Ernst et al., 2016). Ultimately, our study demonstrates
a method to identify the plant lineages that are most important
ethnomedicinally. As research into natural products grows,
this framework provides novel insights into how knowledge of
ethnomedicinal plants is distributed and might be used.
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